Julian

“Really quickly on DD, just curious if anything has changed and how you may be prioritizing external innovation versus internal, especially with the announcement disclosed last week.”

“And I guess just to to piggyback again on the orexin program and the pipeline would be great to hear about for this larger phase two that you're kicking off this summer um what types of patients are you hoping to enroll and can you just talk a little bit about the translatability of what you'd expect based on you know…”

“I guess primarily, are there any paths that you can potentially pursue in order to push your agenda beyond just the traditional FDA channels here? I'm curious like what other levers you can pull to potentially garner support for registration based on either the existing data or the four-year data.”

“I mean, do you think you're going to have to do a full development plan, or is this bridging study you can do to get it to market?”